Consensus Virbac

Equities

VIRP

FR0000031577

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:37:42 2025-06-20 am EDT			5-day change	1st Jan Change
323.50 ^EUR	+0.15%		+1.73%	+2.21%

Jun. 19	Virbac SA Appoints Paul Martingell as Chief Executive Officer, Effective September 1, 2025	CI
Jun. 19	France's Virbac Names New CEO	MT

Evolution of the Average Target: Virbac

Evolution of the Target Price: Virbac

Changes in Analyst Recommendations: Virbac

4.wFy-IhogZ0DgyasBIE2WaNC2Uvd2uY6uE6JMmocEKfM.nxLfVFRNUTiwqsg5VH3nWoTkGMYm8fyaW8YqwPZjZ4uiGokbI1QGEqm-6g~9be05e46bf6bbfaa4fb6cd4ebc983c85

Analysts' recommendations: Virbac

VIRBAC : Decent Q1; Clarity on US tariff exposure was a key takeaway	Apr. 16
VIRBAC : Stifel still buying after Q1 results	Apr. 16	CF
VIRBAC : Oddo BHF remains 'neutral', confirms its target	Mar. 17	CF
VIRBAC : 2024 profitability somewhat exceeded expectations; stock re-rating underway	Mar. 17
VIRBAC : Stifel raises its recommendation	Mar. 17	CF
VIRBAC : 2024 top-line goals met; uninspiring 2025 outlook could be raised later	Jan. 17
Oddo BHF Downgrades Virbac to Neutral, Cuts PT	Jan. 17	MT
VIRBAC : Market’s anxiety over the Q3 miss was not warranted	24-10-18
VIRBAC : Making good strides	24-10-01
TP ICAP Midcap Upgrades Virbac to Buy	24-07-30	MT
VIRBAC : Robust Q2 was already baked in after the recent guidance upgrade	24-07-17
VIRBAC : Virbac remains an attractive animal healthcare play	24-05-03
VIRBAC : A healthy start to 2024; outlook re-iterated	24-04-17
VIRBAC : Modest beat in Q4; 2024 outlook maintained	24-01-18
Stifel Keeps Virbac at Hold, Boosts PT	24-01-18	MT
VIRBAC : Onboarding some steady improvements	23-12-22
VIRBAC : On course for a better-than-expected 2023 finish	23-12-20
Oddo BHF Keeps Virbac at Outperform, Boosts PT	23-12-20	MT
VIRBAC : Factoring in the improved 2023 outlook	23-10-26
VIRBAC : A rebound in Q3; outlook improved; markets jubilant	23-10-24
Oddo BHF Upgrades Virbac to Outperform from Neutral, Lifts PT	23-10-24	MT
VIRBAC : H1 profitability pressure less severe than expected	23-10-03
Stifel Downgrades Virbac to Keep from Buy, Cuts PT	23-08-21	MT
VIRBAC : In line Q2; markets coming to terms with the previously-moderated guidance	23-07-19
VIRBAC : Capacity constraints (temporary?) and a market slowdown weigh on near-term earnings	23-07-07

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	VIRBAC					+19.58%
	ZOETIS INC.					+24.09%
	ELANCO ANIMAL HEALTH INCORPORATED					+10.43%
	BLUESTAR ADISSEO COMPANY					+22.16%
	VIMIAN GROUP AB					+16.63%
	TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.					+36.93%
	CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.					+10.89%
	WUHAN KEQIAN BIOLOGY CO.,LTD					+42.53%
	PHIBRO ANIMAL HEALTH CORPORATION					-6.83%
	VETOQUINOL SA					+30.82%
	Average					+20.72%
	Weighted average by Cap.					+22.64%